Advertisement

Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach

      Highlights

      • Fresh-frozen-tissue (FFT) based BRCA screening workflow is feasible and reliable
      • The concordance of tumor test versus germline BRCA test was 86.3%.
      • FFT-screening led us to identify 6% of patients with tumor BRCA mutation only, who might be eligible for PARPi treatment

      Abstract

      Objective

      For many years, BRCA mutational status has only been considered as a predictor of ovarian cancer susceptibility and as a prognostic factor. Nonetheless, in the era of precision medicine, it has also become a predictive biomarker of response to platinum-based-chemotherapy and, more recently, to PARP-inhibitors, also in the frontline setting.
      We assessed the feasibility of a fresh frozen tissue-based-BRCA-screening workflow in a tertiary referral center.

      Methods

      We consecutively enrolled a series of 456 newly diagnosed FIGO-Stage IIIC-IV, high grade serous-ovarian cancer patients. All patients receiving tumor-biopsy underwent tBRCA-testing.

      Results

      Clinically relevant tissue-BRCA (tBRCA) variants were observed in 145 women (31.8%), particularly we recognized 89 (61.4%) patients with BRCA1-pathogenetic variants (PVs) and 56 women (38.6%) with BRCA2-PVs. Among 292 tBRCA wild-type (wt) patients, 88 cases were germline BRCA tested (gBRCA) and 86 (97.8%) were confirmed as gBRCAwt, while 1 (1.1%) had gBRCA variant of uncertain significance and 1 had gBRCA mutation (1.1%).
      The concordance of tumor test versus germline BRCA test was 86.3% (209/242).
      Large genomic rearrangements (LGRs) were suspected in 13/292 tBRCAwt patients (4.5%) by using bioinformatic algorithm and multiplex ligation-dependent probe amplification (MLPA) was performed, with evidence of PVs in only 1 case.

      Conclusions

      Fresh-frozen tissue-based BRCA screening workflow is feasible and reliable. It allows to enlarge the BRCA mutated population that might receive PARPi with the greatest benefit, without missing cascade testing for family members and therefore, maintaining its preventive role.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. National Cancer Institute (NIH), Surveillance, Epidemiology and End Results Program: Ovarian cancer section. Available online: https://seer.cancer.gov/statfacts/html/ovary.html;

      2. K.B. Kuchenbaecker, J. L. Hopper, D. R. Barnes et al.“Risks of Breast, Ovarian and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers”. Journal of the American Medical Association-2017;

      3. Moore K, Colombo N, Scambia G, et al: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495–2505;

        • Tonin P.
        • Serova O.
        • Simard J.
        • et al.
        The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21.
        Hum. Mol. Genet. 1994; 3: 1679-1682
        • Wooster R.
        • Neuhausen S.L.
        • Mangion J.
        • et al.
        Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
        Science. 1994; 265: 2088-2090
        • Konstantinopoulos P.A.
        • Norquist B.
        • Lacchetti C.
        • et al.
        Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
        J. Clin. Oncol. 2020 Jan; 27JCO1902960
        • Merajver S.D.
        • Pham T.M.
        • Caduff R.F.
        • et al.
        Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
        Nat. Genet. 1995 Apr; 9: 439-443
        • Foster K.A.
        • Harrington P.
        • Kerr J.
        • et al.
        Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.
        Cancer Res. 1996 Aug 15; 56: 3622-3625
        • Berchuck A.
        • Heron K.A.
        • Carney M.E.
        • et al.
        Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
        Clin. Cancer Res. 1998 Oct; 4: 2433-2437
        • Cancer Genome Atlas Research Network
        Integrated genomic analyses of ovarian carcinoma.
        Nature. 2011 Jun 29; 474: 609-615
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • et al.
        Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
        Lancet Oncol. 2014 Jul; 15: 852-861
      4. Endris V, Stenzinger A, Pfarr N et al. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Arch. 2016 Jun;468(6):697–705);

      5. Vos JR, Fakkert IE, de Hullu JA et al. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. JNCI J Natl Cancer Inst (2020) 112(2): djz080;

        • Morganti S.
        • Tarantino P.
        • Ferraro E.
        • et al.
        Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
        Adv. Exp. Med. Biol. 2019; 1168: 9-30
      6. Ferrer I, Armstrong J, Capellari S et al. Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol 17(3):297–303. doi:https://doi.org/10.1111/j.1750-3639.2007. 00073;

      7. Callens C, Vaur D, Soubeyran I, et al. BRCA&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial. Annals of Oncology (2017) 28 (suppl_5): v330-v354. https://doi.org/10.1093/annonc/mdx372;

        • Enyedi M.Z.
        • Jaksa G.
        • Pintér L.
        • et al.
        Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
        Oncotarget. 2016 Sep 20; 7: 61845-61859
        • Lee A.
        • Kang J.
        • Lee H.
        • Lee Y.S.
        • et al.
        BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
        Pathol. Res. Pract. 2019 Nov; 215: 152595
        • Mafficini A.
        • Simbolo M.
        • Parisi A.
        • et al.
        BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
        Oncotarget. 2016 Jan 12; 7: 1076-1083
        • Petrillo M.
        • Vizzielli G.
        • Fanfani F.
        • et al.
        Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept.
        Gynecol. Oncol. 2015; 139: 5-9
        • Aletti G.D.
        • Eisenhauer E.L.
        • Santillan A.
        • Axtell A.
        • Aletti G.
        • Holschneider C.
        • et al.
        Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.
        Gynecol. Oncol. 2011; 120: 23-28
        • Costella A.
        • De Leo R.
        • Guarino D.
        • D’Indinosante M.
        • Concolino P.
        • Mazzuccato G.
        • Urbani A.
        • Scambia G.
        • Capoluongo E.
        • Fagotti A.
        • Minucci A.
        High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report.
        Hum Genome Var. 2018 Jun 8; 5: 10
        • Concolino P.
        • Rizza R.
        • Mignone F.
        • et al.
        A comprehensive BRCA1/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis.
        Clin. Chim. Acta. 2018 May; 480: 173-179
      8. Minucci A, Mazzuccato G, Marchetti C. et al: Detecting germline rearrangements of BRCA1 by next generation tumor sequencing. Mol. Biol. in press (2020);

        • Goncalves S.
        • Gomez Abuin G.
        • Gallardo D.
        • et al.
        11 Flabra, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population.
        A Latin America (LA) Epidemiologic Study International Journal of Gynecologic Cancer. 2019; 29: A7
        • Schemper M.
        • Smith T.L.
        A note on quantifying follow-up in studies of failure time.
        Control. Clin. Trials. 1996; 17: 343-346
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observation.
        J. Am. Stat. Assoc. 1958; 53: 457-481
        • Mantel N.
        Evaluation of survival data and two new rank order statistics arising in its consideration.
        Cancer. Chem. Rep. 1966; 50: 163-170
        • Marchetti C.
        • De Leo R.
        • Musella A.
        • et al.
        BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
        Ann. Surg. Oncol. 2018 Nov; 25: 3701-3708
        • Nedelcu R.
        • Liede A.
        • Aubé J.
        • et al.
        BRCA mutations in Italian breast/ovarian cancer families.
        Eur. J. Hum. Genet. 2002 Feb; 10: 150-152
      9. Ray-Coquard IL, Pautier P, Pignata S, et al: Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Ann Oncol 30, 2019 (suppl 5; abstr LBA2_PR);

      10. Gonzalez-Martın A, Pothuri B, Vergote I et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1910962;

        • Badoer C.
        • Garrec C.
        • Goossens D.
        • et al.
        Performance of multiplicom’s BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
        Oncotarget. 2016 Dec 6; 7: 81357-81366
      11. Petrillo M, Marchetti C, De Leo R et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017 Sep;217(3): 334.e1–334.e9.

      12. Kwon JS, Tinker AV, TA, Karsanc A, et al: Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a companion diagnostic for PARP inhibitor treatment. Presented at the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer, Honolulu, HI, March 16–19, 2019.